Hepion continues to make progress with the addition of another dose cohort (375mg) to the ongoing CRV431 Phase I clinical trial since dose-limiting side effects were not yet observed at doses up to 300mg. The company also announced preclinical data stating that CRV431 demonstrated anti-fibrotic effects on kidney fibrosis.
08 Jul 2020
Hepion Pharmaceuticals - Phase I clinical trial nearing completion
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hepion Pharmaceuticals - Phase I clinical trial nearing completion
Hepion Pharmaceuticals, Inc. (HEPA:NAS) | 0 0 0.0%
- Published:
08 Jul 2020 -
Author:
Anne Margaret Crow -
Pages:
6
Hepion continues to make progress with the addition of another dose cohort (375mg) to the ongoing CRV431 Phase I clinical trial since dose-limiting side effects were not yet observed at doses up to 300mg. The company also announced preclinical data stating that CRV431 demonstrated anti-fibrotic effects on kidney fibrosis.